RecruitingPhase 2NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Studying Von Hippel-Lindau disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 322 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California, United States
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois, United States
- Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville, Illinois, United States
- University of Iowa ( Site 0104), Iowa City, Iowa, United States
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore, Maryland, United States
- National Institutes of Health ( Site 0125), Bethesda, Maryland, United States
- Massachusetts General Hospital ( Site 0111), Boston, Massachusetts, United States
- University of Michigan ( Site 0126), Ann Arbor, Michigan, United States
- Washington University-Internal Medicine/Oncology ( Site 0124), St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York, New York, United States
- Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127), Philadelphia, Pennsylvania, United States
- SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
- Vanderbilt University Medical Center ( Site 0107), Nashville, Tennessee, United States
- University of Texas MD Anderson Cancer Center ( Site 0112), Houston, Texas, United States
- Prince of Wales Hospital-Medical Oncology ( Site 1601), Randwick, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04924075 on ClinicalTrials.govOther trials for Von Hippel-Lindau disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07171905CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau DiseaseIRCCS Ospedale San Raffaele
- ENROLLING BY INVITATIONNANCT05737602Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau DiseaseMassachusetts General Hospital
- RECRUITINGPHASE2NCT07167329Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialJosé Claudio Casali da Rocha
- RECRUITINGNCT05955014Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center
- RECRUITINGNCT06194669Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule CellsIRCCS San Raffaele
- RECRUITINGNANCT05424016Propranolol and Von Hippel-Lindau DiseaseAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGNCT04458935Retrospective Case Series of Trans-scleral Cryotherapy for Retinal HemangioblastomaNational Eye Institute (NEI)